University of Pennsylvania Center for Studies of Addiction
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT02011516
Studies show that certain reminders of drug use such as the sight of someone using marijuana, pictures of blunts, particular moments throughout the day, prompt marijuana users to smoke marijuana. We are measuring the brain and behavioral responses of marijuana dependent individuals to these reminders (cues) We will examine brain responses during cue exposure and determine whether these responses are associated with treatment outcome.
We are testing the hypothesis that the medication baclofen reduces brain responses during marijuana cue exposure and/or craving in marijuana dependent individuals. Baclofen is FDA-approved for other uses, but not for the treatment of marijuana dependence. Functional magnetic resonance imaging (fMRI) will be used to measure the brain's response to marijuana cues. fMRI is a painless technique that takes special pictures of the brain (or other parts of your body). It does not involve radiation or injections.
Eligible participants will have a 50% chance of receiving placebo (sugar pill) and a 50% chance of receiving baclofen. Neither the participant nor study personnel will know whether participants are receiving baclofen or placebo. Participants will also receive twice weekly psychosocial treatment with a certified clinician. Twelve weeks of treatment will be followed by a 12 week follow up.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2
Philadelphia, Pennsylvania, 19104, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Case-by-Case:
Other names: Kemstro, Lioresal, Liofen, Gablofen, Beklo
Other names: Sugar pill
Time frame: study weeks 1-12
Change from positive to negative over the 12 weeks of a medication regimen
University of Pennsylvania
Other
A Randomized Placebo-controlled Study of Baclofen on Brain and Behavioral Outcomes in Marijuana Dependence
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00480441
Behavior, Behavior, Addictive
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07340554
Addiction, Addiction, Substance
Indianapolis, Indiana, United States
View Trial DetailsNCT04965012
Behavior, Chemically-Induced Disorders
Winnipeg, Manitoba, Canada
View Trial DetailsNCT02955329
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial Details